RxDoctor Payments Data

Donald Clarke, MD

Family Medicine · Goldsboro, NCNPI 1326138496

Payments from drug & device makers

$11,699in general payments, 2019–2025

Across 759 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Lilly USA, LLC$892
  • Merck$765
  • Pfizer$754
  • AstraZeneca$689
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,690100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,699 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$180,241
Medicare patients
463
Services billed
3,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$152,430
EliquisApixaban196$144,781
TrulicityDulaglutide130$140,755
Cosentyx Sensoready (2 Pens)Secukinumab16$132,240
JardianceEmpagliflozin149$131,077
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$70,976
EntrestoSacubitril/Valsartan55$40,431
RybelsusSemaglutide27$40,341
FarxigaDapagliflozin Propanediol50$38,391
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$36,778
LinzessLinaclotide47$32,348
JanuviaSitagliptin Phosphate42$29,088
XareltoRivaroxaban45$26,761
KerendiaFinerenone33$21,020
CreonLipase/Protease/Amylase14$20,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,867$192,771177 claims
PfizerEliquis$754$144,781196 claims
Lilly USA, LLCTrulicity$892$140,755130 claims
Boehringer IngelheimJardiance$611$131,077149 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$515$114,368193 claims
AbbVieLinzess, Creon, Synthroid$1,676$62,020150 claims
MerckJanuvia, Janumet Xr$765$40,94256 claims
NovartisEntresto$332$40,43155 claims
AstraZenecaFarxiga$689$38,39150 claims
Johnson & JohnsonXarelto$69$26,76145 claims
BayerKerendia$242$21,02033 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$101$9,87416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →